Completed PHASE2 INTERVENTIONAL NCT00141505

PK Effects of Bifeprunox & Valproate in Bipolar I

Placebo-controlled Study on the Pharmacokinetics,Pharmacodynamics, Safety and Tolerability of Concurrent Valproate and Bifeprunox Administration in Subjects With Bipolar I Disorder

Sponsor: H. Lundbeck A/S

Conditions Bipolar I Disorder

Interventions Bifeprunox

Updated 5 times since 2017 Last updated: Jan 15, 2015 Started: Feb 28, 2005 Primary completion: Dec 31, 2006 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Bipolar I Disorder, this trial is completed. The trial is conducted by H. Lundbeck A/S and has accumulated 5 data snapshots since 2005. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

H. Lundbeck A/S
Solvay Pharmaceuticals
Wyeth is now a wholly owned subsidiary of Pfizer

Data source: Solvay Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Atlanta, United States